These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 31897746)
1. Bazedoxifene improves renal function and increases renal phosphate excretion in patients with postmenopausal osteoporosis. Masaki H; Imanishi Y; Naka H; Nagata Y; Kurajoh M; Mori K; Emoto M; Miki T; Inaba M J Bone Miner Metab; 2020 May; 38(3):405-411. PubMed ID: 31897746 [TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status. Adami S; Palacios S; Rizzoli R; Levine AB; Sutradhar S; Chines AA Climacteric; 2014 Jun; 17(3):273-84. PubMed ID: 23937421 [TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function. Dhayat NA; Ackermann D; Pruijm M; Ponte B; Ehret G; Guessous I; Leichtle AB; Paccaud F; Mohaupt M; Fiedler GM; Devuyst O; Pechère-Bertschi A; Burnier M; Martin PY; Bochud M; Vogt B; Fuster DG Kidney Int; 2016 Sep; 90(3):648-57. PubMed ID: 27370409 [TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 23, but not parathyroid hormone, is associated with urinary phosphate regulation in patients on peritoneal dialysis. Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Hasegawa S; Tanaka S; Eriguchi M; Nakano T; Masutani K; Ooboshi H; Kitazono T Ther Apher Dial; 2015 Feb; 19(1):73-80. PubMed ID: 25195562 [TBL] [Abstract][Full Text] [Related]
5. Parathyroid Hormone, Fibroblast Growth Factor 23, and Parameters of Phosphate Reabsorption. Phelps KR; Mason DL Am J Nephrol; 2018; 47(5):343-351. PubMed ID: 29779023 [TBL] [Abstract][Full Text] [Related]
6. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Miller PD; Schwartz EN; Chen P; Misurski DA; Krege JH Osteoporos Int; 2007 Jan; 18(1):59-68. PubMed ID: 17013567 [TBL] [Abstract][Full Text] [Related]
7. Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide. Takeuchi Y; Kuroda T; Sugimoto T; Shiraki M; Nakamura T Calcif Tissue Int; 2016 Feb; 98(2):186-92. PubMed ID: 26478225 [TBL] [Abstract][Full Text] [Related]
8. The effect of alendronate on renal tubular reabsorption of phosphate. Vasikaran SD; O'Doherty DP; McCloskey EV; Gertz B; Kahn S; Kanis JA Bone Miner; 1994 Oct; 27(1):51-6. PubMed ID: 7849546 [TBL] [Abstract][Full Text] [Related]
9. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis. Joseph F; Ahmad AM; Ul-Haq M; Durham BH; Whittingham P; Fraser WD; Vora JP J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753 [TBL] [Abstract][Full Text] [Related]
10. Serum level of fibroblast growth factor 23 in maintenance renal transplant patients. Sánchez Fructuoso AI; Maestro ML; Pérez-Flores I; Valero R; Rafael S; Veganzones S; Calvo N; De la Orden V; De la Flor JC; Valga F; Vidaurreta M; Fernández-Pérez C; Barrientos A Nephrol Dial Transplant; 2012 Nov; 27(11):4227-35. PubMed ID: 23144073 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. Palacios S Curr Med Res Opin; 2010 Jul; 26(7):1553-63. PubMed ID: 20429824 [TBL] [Abstract][Full Text] [Related]
12. Denosumab Improves Glomerular Filtration Rate in Osteoporotic Patients With Normal Kidney Function by Lowering Serum Phosphorus. Miyaoka D; Inaba M; Imanishi Y; Hayashi N; Ohara M; Nagata Y; Kurajoh M; Yamada S; Mori K; Emoto M J Bone Miner Res; 2019 Nov; 34(11):2028-2035. PubMed ID: 31273841 [TBL] [Abstract][Full Text] [Related]
13. Effects of norethisterone on bone related biochemical variables and forearm bone mineral in post-menopausal osteoporosis. Horowitz M; Wishart JM; Need AG; Morris HA; Nordin BE Clin Endocrinol (Oxf); 1993 Dec; 39(6):649-55. PubMed ID: 8287582 [TBL] [Abstract][Full Text] [Related]
14. Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis. Kung AW; Chu EY; Xu L Expert Opin Pharmacother; 2009 Jun; 10(8):1377-85. PubMed ID: 19445558 [TBL] [Abstract][Full Text] [Related]
15. Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis. de Villiers TJ Climacteric; 2010 Jun; 13(3):210-8. PubMed ID: 20184423 [TBL] [Abstract][Full Text] [Related]
16. Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis. Genant HK Menopause Int; 2011 Jun; 17(2):44-9. PubMed ID: 21693498 [TBL] [Abstract][Full Text] [Related]
17. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112 [TBL] [Abstract][Full Text] [Related]
18. Phosphate handling by end-stage kidneys and benefits of residual renal function on phosphate removal in patients on haemodialysis. Iwasawa H; Nakao T; Matsumoto H; Okada T; Nagaoka Y; Wada T Nephrology (Carlton); 2013 Apr; 18(4):285-91. PubMed ID: 23432763 [TBL] [Abstract][Full Text] [Related]
19. The effects of bazedoxifene on bone structural strength evaluated by hip structure analysis. Beck TJ; Fuerst T; Gaither KW; Sutradhar S; Levine AB; Hines T; Yu CR; Williams R; Mirkin S; Chines AA Bone; 2015 Aug; 77():115-9. PubMed ID: 25917574 [TBL] [Abstract][Full Text] [Related]
20. Association of cystatin C- and creatinine-based eGFR with osteoporotic fracture in Japanese postmenopausal women with osteoporosis: sarcopenia as risk for fracture. Kurajoh M; Inaba M; Nagata Y; Yamada S; Imanishi Y; Emoto M J Bone Miner Metab; 2019 Mar; 37(2):282-291. PubMed ID: 29464358 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]